Cargando…

The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy

PURPOSE: Neoadjuvant chemoradiotherapy (nCRT) is a standard treatment option for patients with stage III oesophageal cancer. Approximately 30% of oesophageal cancer patients will have a pathological complete response (pCR) after nCRT. However, available clinical methods cannot accurately predict pCR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jin, Lin, Hai-Ping, Xu, Xin, Wang, Xiao-Hang, Rong, Ling, Zhang, Yao, Shen, Lei, Xu, Lei, Qin, Wei-Ting, Ye, Qing, Ma, Xiu-Mei, Bai, Yong-Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701713/ https://www.ncbi.nlm.nih.gov/pubmed/36451825 http://dx.doi.org/10.3389/fimmu.2022.1041126

Ejemplares similares

MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma
por: Luo, Qiyu, et al.
Publicado: (2021)

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by radical surgery for locally advanced oesophageal squamous cell carcinoma: meta-analysis
por: Kamarajah, Sivesh K, et al.
Publicado: (2022)

Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients Treated with Definitive Chemoradiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma
por: Zhang, Guojun, et al.
Publicado: (2023)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison
por: Eyck, Ben M, et al.
Publicado: (2022)

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
por: Sun, Hai-Bo, et al.
Publicado: (2020)

Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer
por: Hagens, E. R. C., et al.
Publicado: (2020)

Controversies in upper gastrointestinal oncology: neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in oesophageal adenocarcinoma
por: Petrillo, A., et al.
Publicado: (2022)

The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy
por: Cox, Samantha, et al.
Publicado: (2017)

Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets
por: Tada, Noriko, et al.
Publicado: (2015)

Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy
por: Yoshikawa, R, et al.
Publicado: (2008)

Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer
por: Vollenbrock, S. E., et al.
Publicado: (2019)

Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer
por: Blazeby, J M, et al.
Publicado: (2014)

Diffusion-weighted MRI and (18)F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
por: Xu, Xin, et al.
Publicado: (2021)

Prognostic implications of the extent of downstaging after neoadjuvant therapy for oesophageal adenocarcinoma and oesophageal squamous cell carcinoma
por: Kamarajah, Sivesh K, et al.
Publicado: (2023)

Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma
por: Duque-Santana, Victor, et al.
Publicado: (2022)

Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommon
por: Valkema, Maria J, et al.
Publicado: (2023)

The effectiveness of neoadjuvant chemoradiotherapy in oesophageal adenocarcinoma with presence of extracellular mucin, signet‐ring cells, and/or poorly cohesive cells
por: Valkema, Maria J, et al.
Publicado: (2023)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma
por: Shimada, H, et al.
Publicado: (2002)

Prognostic value of peripheral blood T lymphocyte subsets in clear cell renal cell carcinoma
por: Zhou, Yihong, et al.
Publicado: (2021)

Persistent Changes of Peripheral Blood Lymphocyte Subsets in Patients with Oral Squamous Cell Carcinoma
por: Caruntu, Ana, et al.
Publicado: (2022)

Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy
por: Li, Ke-Jie, et al.
Publicado: (2019)

Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies
por: de Klerk, Leonie K., et al.
Publicado: (2021)

Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma
por: Wen, Jing, et al.
Publicado: (2022)

Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy
por: Yang, Yang, et al.
Publicado: (2020)

Oesophageal squamous cell carcinoma: histogram-derived ADC parameters are not predictive of tumour response to chemoradiotherapy
por: Kozumi, Maiko, et al.
Publicado: (2018)

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis
por: Guo, Yaru, et al.
Publicado: (2022)

Feasibility, safety and oncological outcomes of minimally invasive oesophagectomy following neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma – Experience from a tertiary care centre
por: Surendran, Suraj, et al.
Publicado: (2022)

Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers
por: Wu, Yingjia, et al.
Publicado: (2021)

Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
por: Yoon, Han Gyul, et al.
Publicado: (2021)

Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer
por: Eyck, Ben M, et al.
Publicado: (2022)

Author response to: Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study
por: Kamarajah, S K, et al.
Publicado: (2021)

Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy
por: Su, Po-Jung, et al.
Publicado: (2016)

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014)

Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
por: Chen, Fei, et al.
Publicado: (2022)

Exploring the clinical application value of peripheral blood T lymphocyte subset in patients with asymptomatic omicron infection
por: Li, Tuantuan, et al.
Publicado: (2023)

Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma
por: Jeong, Hyehyun, et al.
Publicado: (2021)

The clinical value of the changes of peripheral lymphocyte subsets absolute counts in patients with non-small cell lung cancer
por: Xia, Ying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_282n7pk7muv49ej33bvepudgot